Form 8-K - Current report:
SEC Accession No. 0001628280-24-052579
Filing Date
2024-12-30
Accepted
2024-12-30 16:23:28
Documents
13
Period of Report
2024-12-22
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20241222.htm   iXBRL 8-K 35522
  Complete submission text file 0001628280-24-052579.txt   160981

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20241222.xsd EX-101.SCH 1824
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20241222_lab.xml EX-101.LAB 21880
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20241222_pre.xml EX-101.PRE 12547
15 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20241222_htm.xml XML 2714
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 241590137
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)